EVENTS & PRESENTATIONS V1
2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Effects of Anti-VEGF and ALG-1001 on Human Retinal Cells In Vitro
To be presented by Cristina Kenney, MD, PhD
April 29, 2018 at 4:00 pm
Hawaii Convention Center, Room 316A, Honolulu, Hawaii
Special Interest Group: Managing Patients with Diabetic Macular Edema, Diabetic Retinopathy, Neovascular and Non-Neovascular AMD, and Retinal Vein Occlusion: How to Best Utillize the Latest Data from Clinical Trials
Faculty includes Peter Campochiaro, Judy Kim, Robert Avery, David Boyer, Diana Do, and Quan Dong Nguyen
April 30, 2018 at 1:30-3:00 pm
Hawaii Convention Center, Room 311, Honolulu, Hawaii
Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety and Efficacy of ALG-1001 (Luminate) in Diabetic Macular Edema
To be presented by Hugo Quiroz-Mercado, MD
April 30, 2018 at 4:45 pm
Hawaii Convention Center, Room 311, Honolulu, Hawaii
American Society of Retina Specialists (ASRS) Annual Meeting 2018
Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety & Efficacy of ALG-1001 (Luminate) in Diabetic Macular Edema
To be presented by Peter K. Kaiser, MD
July 24, 2018 at 8:36 am
Vancouver Convention Center, Vancouver, CanadaISOPT Clinical 2018
Randomized, Prospective, Double-Masked, Controlled Phase 2b Trial to Evaluate the Safety and Efficacy of ALG-1001 (Luminate) in DME
Presented by Baruch D. Kuppermann, MD, PhD
March 1, 2018
Tel-Aviv, Israel
Angiogenesis, Exudation, and Degeneration 2018
Integrin Antagonism and Diabetic Macular Edema
Presented by Peter K. Kaiser, MD
February 10, 2018
Miami, FL
Hawaiian Eye & Retina 2018
Prospective, Double-Masked, Placebo-Controlled Phase 2b Trial on the Safety and Efficacy of ALG-1001 (Luminate) in DME
Presented by Peter K. Kaiser, MD
January 17, 2018
Maui, HawaiiAAO 2017
Prospective, Double-Masked, Placebo-Controlled Phase 2b Trial on the Safety and Efficacy of ALG-1001 (Luminate®) in Diabetic Macular Edema
Presented by Baruch D Kuppermann, MD, PhD
November 12, 2017
New Orleans, LA
Ophthalmology Innovation Summit @ASRS 2017
Luminate® for the Treatment of Diabetic Macular Edema
Presented by Vicken Karageozian, MD, President & Chief Medical Officer, Allegro Ophthalmics
August 10, 2017
Boston, MA
American Society of Retina Specialists (ASRS) 2017 Annual Meeting
Topline Results From Prospective, Double-Masked Phase 2b Clinical Trial Evaluating ALG-1001 Luminate® Compared to Bevacizumab in Patients With DME
Presented by David S. Boyer, MD
August 15, 2017
Boston, MA
ARVO 2017
Topline Results From Prospective, Double-masked, Placebo Controlled Phase 2b Clinical Study Evaluating Luminate® in Patients with Diabetic Macular Edema
Presented by Peter Kaiser, MD
May 8, 2017
Baltimore, MD
ARVO 2016
Topline Results From Prospective, Double-masked, Placebo Controlled Phase 2 Study Evaluating Luminate® (ALG-1001) in Patients with Symptomatic Focal Vitreomacular Adhesion
Presented by Baruch Kuppermann, MD, PhD
May 2, 2016
Seattle, WA
Ocular Diseases Drug Discovery Meeting 2016
Integrin Peptide Therapy: Looking Past Anti-VEGF for Retinovascular Diseases
Presented by Vicken Karageozian, MD, Chief Technical Officer, Allegro Ophthalmics
March 21, 2016
San Diego, CA
Vail Vitrectomy 2016
Pharmacologic Induction of a Posterior Vitreous Detachment and Potential Impact on Surgical Vitrectomy
Presented by Baruch Kuppermann, MD, PhD
February 22, 2016
Vail, CO
World Ophthalmic Congress (WOC) 2016
Emerging Pharmacotherapies for Posterior Segment Diseases
Presented by Baruch Kuppermann, MD, PhD
February 8, 2016
Guadalajara, MexicoOphthalmology Innovation Summit (OIS@AAO) 2015
Luminate® for the Treatment of Retinal Diseases
Presented by Vicken Karageozian, MD, CTO, Allegro Ophthalmics
November 12, 2015
Las Vegas, NV
American Academy of Ophthalmology (AAO) Meeting 2014
Update on Integrin Antagonists
Presented by Hugo Quiroz-Mercado, MD, Professor of Ophthalmology, University of Colorado School of Medicine (Denver, CO)
October 17, 2014
Chicago, IL
Ophthalmology Innovation Summit (OIS) 2014
Luminate® for the Treatment of Retinal Eye Diseases
Presented by Vicken Karageozian, MD, CTO, Allegro Ophthalmics.
October 16, 2014
Chicago, IL
World Ophthalmology Congress 2014
Integrin Inhibition for Wet AMD
Presented by Peter Kaiser, MD, Staff member of the vitreoretinal faculty of the Cole Eye Institute in the Department of Ophthalmology at Cleveland Clinic.
April 4, 2014
Tokyo, Japan
Angiogenesis, Exudation, and Degeneration Meeting 2014
Integrin Antagonism in AMD, DME and VMT
Presented by Hugo Quiroz-Mercado, MD, Professor of Ophthalmology, University of Colorado School of Medicine (Denver, CO)
February 8, 2014 from 3:20-3:30
Miami, FL
American Academy of Ophthalmology (AAO) Meeting 2013
Integrin Peptide Therapy: The First Human Wet AMD Experience
Presented by David Boyer, MD
November 19, 2013
Ophthalmology Innovation Summit (OIS) 2013
Allegro Ophthalmics: Accelerated Innovation. Needed Intervention
Presented by Vicken Karageozian, MD, Co-Founder & CTO, Allegro Ophthalmics
November 14, 2013
New Orleans, LA
Partnering for Cures (P4C) 2013
A Faster Way Forward: Allegro’s Innovative Approach to The Science & Business of Drug Development
Presented by Vicken Karageozian, MD, Co-Founder & CTO, Allegro Ophthalmics
November 4, 2013
New York City, NY
Retinal Innovation Forum at the American Society of Retina Specialists (ASRS) Meeting 2013
Integrin Peptide Therapy: A Novel Approach to Neovascular Eye Diseases
Presented by Vicken Karageozian, MD, Co-Founder and Chief Technical Offer at Allegro Ophthalmics
August 26, 2013
Toronto, Ontario
Association for Research in Vision and Ophthalmology (ARVO) Meeting 2013
Integrin Peptide Therapy: The First Wet AMD Experience
Presented by Peter Kaiser, MD
May 6, 2013American Academy of Ophthalmology (AAO) Meeting 2012
Integrin Peptide Therapy: The Latest Human Clinical Update
Presented by Barry Kuppermann, MD PhD
November 12, 2012
45th Annual Retina Society Meeting 2012
Integrin Peptide Therapy: The First Human Diabetic Macular Edema (DME) Experience in a Phase 1 Trial
October 7, 2012
Washington, DC
30th Annual American Society of Retina Specialists (ASRS) Meeting 2012
Integrin Peptide Therapy: The Human Experience in DME
Presented by Dr. Hugo Quiroz-Mercado, MD
August 27, 2012
Las Vegas, Nevada
Club Jules Gonin 2012
Integrin Peptide Therapy: A New Class of Treatment for Vascular Eye Diseases – The First Human Experience in DME
Presented by Hugo Quiroz-Mercado, MD
June 20-12, 2012
Association for Research in Vision and Ophthalmology (ARVO) Meeting 2012
Diabetic Retinopathy- Clinical Research II
Presented by David Boyer, MD
May 6-10, 2012
World Ophthalmology Congress 2012
Integrin Inhibition as an Antiangiogenic Strategy for the Treatment of Posterior Segment
Presented by Baruch Kuppermann, MD, PhD
February 19, 2012
ISOPT Clinical 2011:
Integrin Inhibition for DME
Presented by Baruch Kuppermann, MD, PhD
December 1-4, 2011
American Academy of Ophthalmology Conference, Retina Subspecialty Day 2011
Integrin Peptide Therapy As The Next Generation Treatment for Vascular Eye Diseases
Presented by Hugo Quiroz-Mercado, MD
October 21, 2011
The Retina Society Annual Scientific Meeting 2011
Phase I Human Safety Study of Integrin Antagonist in Diabetic Retinopathy Subjects
Presented by Hugo Quiroz-Mercado, MD
September 22, 2011
